In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Mary E. Rinella, MD, FAASLD
Professor of Medicine
Director, Metabolic and Fatty Liver Disease
University of Chicago Medicine
Chicago, IL
Dr. Rinella has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boehringer Ingelheim, CytoDyn, GSK, HistoIndex, Incyte, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Sonic, Takeda
Faculty:
Naga Chalasani, MD, FACG, FAASLD, AGAF
David W. Crabb Professor of Gastroenterology and Hepatology
Indiana University School of Medicine
Vice President for Academic Affairs
Indiana University Health
Indianapolis, IN
Dr. Chalasani has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Akero, Altimmune, BioMed, GSK, Ipsen, Madrigal Pharmaceuticals, Merck, Pfizer, Zydus
Ownership Interest: Avant Santé, Heligenics
Research: Boehringer Ingelheim, Exact Sciences
Mazen Noureddin, MD, MHSc
Professor of Clinical Medicine
Lynda K. and David M. Underwood Center for Digestive Disorders
Department of Medicine
Sherrie & Alan Conover Center for Liver Disease & Transplantation
Houston Methodist Research Institute
Houston Methodist Hospital
Houston, TX
No relevant financial relationships have been reported at this time.
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Rosanne Strauss, PharmD, has nothing to disclose.